Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Discusses progress in linking the biology of ovarian cancer with novel targets and innovative therapies entering clinical trials
Provides an up-to-date perspective on successful therapeutic developments as a partnership between laboratory-based and clinical-based research scientists
Identifies those areas of translational research which we believe have shown the most promise, or are likely to do so, in the treatment of ovarian cancer
Despite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging.
In this text, all these areas are covered by experts in the field. Each chapter provides up-to-date coverage of clinical information, prefaced by a description of the rational basis for the selection of each target area and consideration of biomarkers that can be used to aid clinical evaluation.
The four editors work together within the Ovarian Cancer Action collaborative research programme in London and they bring a wealth of laboratory and clinical expertise to this topic. The text should provide an invaluable source of reference for clinical and laboratory-based researchers working to meet the challenges of ovarian cancer.